AIMS/HYPOTHESIS: In type 1 diabetic patients with microalbuminuria not receivingantihypertensive treatment, an increase in urinary AER (UAER) of 6-14%/year and a risk of developing diabetic nephropathy (DN) of 3-30%/year have been reported. We audited the long-term effect of blocking the renin-angiotensin-aldosterone system (RAAS) with an ACE inhibitor (ACEI) or angiotensin II receptor blocker (ARB) in microalbuminuric type 1 diabetic patients on progression of microalbuminuria and development of DN. METHODS:All patients with type 1 diabetes and persistent microalbuminuria (30-300 mg/24 h) were identified (n=227) in 1995 at Steno Diabetes Center and followed for 11 years. Development of DN was defined as a UAER of >300 mg/24 h in two of three consecutive urine samples. RESULTS: Age and duration of diabetes at baseline (mean+/-SD) were 46+/-15 and 28+/-13 years, respectively. During follow-up 14 patients emigrated and 58 (26%) died. Over the same period 79% were treated with an ACEI or ARB. There was a mean decline in UAER of 4%/year. Sixty-five patients (29%) progressed to overt DN, corresponding to 3.1%/year. However, 29 of them regressed to normo- or microalbuminuria on intensified antihypertensive treatment. Glycaemic control and blood pressure remained nearly unchanged. CONCLUSIONS/ INTERPRETATION: In our outpatient clinic, the implementation of RAAS-blocking treatment in type 1 diabetic patients with microalbuminuria successfully reduced long-term progression to overt DN to a rate similar to those previously reported in randomised, double-blind intervention trials of shorter duration using RAAS blockade.
RCT Entities:
AIMS/HYPOTHESIS: In type 1 diabeticpatients with microalbuminuria not receiving antihypertensive treatment, an increase in urinary AER (UAER) of 6-14%/year and a risk of developing diabetic nephropathy (DN) of 3-30%/year have been reported. We audited the long-term effect of blocking the renin-angiotensin-aldosterone system (RAAS) with an ACE inhibitor (ACEI) or angiotensin II receptor blocker (ARB) in microalbuminuric type 1 diabeticpatients on progression of microalbuminuria and development of DN. METHODS: All patients with type 1 diabetes and persistent microalbuminuria (30-300 mg/24 h) were identified (n=227) in 1995 at Steno Diabetes Center and followed for 11 years. Development of DN was defined as a UAER of >300 mg/24 h in two of three consecutive urine samples. RESULTS: Age and duration of diabetes at baseline (mean+/-SD) were 46+/-15 and 28+/-13 years, respectively. During follow-up 14 patients emigrated and 58 (26%) died. Over the same period 79% were treated with an ACEI or ARB. There was a mean decline in UAER of 4%/year. Sixty-five patients (29%) progressed to overt DN, corresponding to 3.1%/year. However, 29 of them regressed to normo- or microalbuminuria on intensified antihypertensive treatment. Glycaemic control and blood pressure remained nearly unchanged. CONCLUSIONS/ INTERPRETATION: In our outpatient clinic, the implementation of RAAS-blocking treatment in type 1 diabeticpatients with microalbuminuria successfully reduced long-term progression to overt DN to a rate similar to those previously reported in randomised, double-blind intervention trials of shorter duration using RAAS blockade.
Authors: G Crepaldi; Q Carta; G Deferrari; R Mangili; R Navalesi; F Santeusanio; A Spalluto; A Vanasia; G M Villa; R Nosadini Journal: Diabetes Care Date: 1998-01 Impact factor: 19.112
Authors: Anne Sofie Astrup; Lise Tarnow; Peter Rossing; Lotte Pietraszek; Peter Riis Hansen; Hans-Henrik Parving Journal: Kidney Int Date: 2005-09 Impact factor: 10.612
Authors: M Porta; J W Hainer; S-O Jansson; A Malm; R Bilous; N Chaturvedi; J H Fuller; R Klein; T Orchard; H-H Parving; A-K Sjølie Journal: Diabetologia Date: 2011-01-12 Impact factor: 10.122
Authors: Sine Knorr; Svend Juul; Birgitte Bytoft; Zuzana Lohse; Tine D Clausen; Rikke B Jensen; Peter Damm; Henning Beck-Nielsen; Elisabeth R Mathiesen; Dorte M Jensen; Claus H Gravholt Journal: Diabetologia Date: 2018-02-24 Impact factor: 10.122